Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12098-023-04618-5 | DOI Listing |
Indian J Med Res
November 2024
Department of Pediatrics, University of Alabama at Birmingham, Division of Pediatric Endocrinology and Diabetes, Alabama, 35233, United States.
J Pediatr Clin Pract
December 2024
Division of Endocrinology and Diabetes, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Front Endocrinol (Lausanne)
December 2024
Rare Disease Research Group, Molecular (Epi) Genetics Laboratory, Bioaraba Health Research Institute, Araba University Hospital, Vitoria-Gasteiz, Spain.
Objective: To identify the genetic cause underlying the methylation defect in a patient with clinical suspicion of PHP1B/iPPSD3.
Design: Imprinting is an epigenetic mechanism that allows the regulation of gene expression. The locus is one of the loci within the genome that is imprinted.
Front Endocrinol (Lausanne)
December 2024
Department of Pediatric Diabetes and Endocrinology, Clinique Pédiatrique, Centre Hospitalier, Luxembourg, Luxembourg.
Aims: To compare impact of pump treatment and continuous glucose monitoring (CGM) with predictive low glucose suspend (SmartGuard) or user initiated CGM (iscCGM) on sleep and hypoglycemia fear in children with type 1 Diabetes and parents.
Methods: Secondary analysis of data from 5 weeks pump treatment with iscCGM (A) or SmartGuard (B) open label, single center, randomized cross-over study was performed. At baseline and end of treatment arms, sleep and fear of hypoglycemia were evaluated using ActiGraph and questionnaires.
Endocrinol Metab (Seoul)
December 2024
Division of Pediatric Endocrinology and Diabetes, Louisiana State University Health Sciences Center, Children's Hospital of New Orleans, New Orleans, LA, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!